On September 26, 2018 Novavax, Inc. (NASDAQ: NVAX) reported that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the first week of October (Press release, Novavax, SEP 26, 2018, View Source [SID1234529628]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details are as follows:

Ladenburg Thalmann 2018 Healthcare Conference

Date and Time: Tuesday, October 2, 12:00 p.m. – 12:25 p.m.
Location: Track 5, Montmartre, Sofitel New York
Live webcast: www.novavax.com, "Investors"/"Events"

Cantor Global Healthcare Conference 2018

Date and Time: Wednesday, October 3, 10:55 a.m. – 11:25 p.m.
Location: Track 2, Empire Ballroom 1, InterContinental New York Barclay Hotel
Live webcast: www.novavax.com, "Investors"/"Events"

On September 26, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:10 a.m. ET at the InterContinental New York Barclay Hotel (Press release, Syndax, SEP 26, 2018, View Source [SID1234529598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the Company’s presentation can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the events will also be available for a limited time.

On September 26, 2018 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York on Wednesday, October 3, 2018 at 3:00 p.m. ET / 12:00 p.m. PT (Press release, Kura Oncology, SEP 26, 2018, View Source [SID1234529614]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

On September 26, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the InterContinental New York Barclay Hotel in New York City (Press release, Alnylam, SEP 26, 2018, View Source;p=RssLanding&cat=news&id=2369007 [SID1234529584]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after the event.

On September 25, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that management will present at two upcoming investor conferences in October (Press release, Fate Therapeutics, SEP 25, 2018, View Source [SID1234529567]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Cantor Global Healthcare Conferenceat 9:10 a.m. ET on Tuesday, October 2, 2018 in New York City.
Leerink Partners Roundtable Series: Rare Disease & Oncology at 8:30 a.m. ET on Wednesday, October 3, 2018 in New York City.

Live webcasts of the presentations will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company’s website.